Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biofrontera ( (BFRI) ) has shared an announcement.
On February 23, 2026, the U.S. Patent Trial and Appeal Board issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries’ U.S. Patent No. 11,697,028 unpatentable, siding with Biofrontera in an inter partes review. The ruling stems from litigation Sun initiated in June 2024 in federal court and the International Trade Commission over alleged patent infringement, and while Sun may still seek rehearing or appeal, the impact on those ongoing proceedings remains uncertain.
The decision leaves a related Sun patent, U.S. Patent No. 11,446,512, unaffected after the Board declined to review it on administrative grounds, meaning aspects of the broader dispute are still unresolved. Biofrontera’s management welcomed the outcome as it potentially eases a key legal overhang tied to its PDT dermatology franchise, though stakeholders must watch for further legal steps by Sun and any subsequent effects on the company’s competitive and regulatory landscape.
The most recent analyst rating on (BFRI) stock is a Hold with a $0.91 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
The score is held down primarily by weak financial performance—persistent operating losses, continued cash burn, and negative equity. Technicals are mixed and do not provide strong confirmation of a durable uptrend, while valuation is difficult to support given negative earnings and no dividend. Offsetting factors include earnings-call guidance targeting FY2026 cash-flow breakeven and margin improvement from acquiring U.S. rights, but near-term listing/compliance risk remains a notable headwind.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatology, specializing in photodynamic therapy (PDT) for treating actinic keratosis and other non-melanoma skin conditions. The company commercializes its Ameluz drug in combination with the RhodoLED lamp series and is conducting clinical trials to expand indications, including non-melanoma skin cancers and moderate-to-severe acne.
Biofrontera targets clinicians treating pre-cancerous and cancerous skin lesions, aiming to grow its position in the dermatology treatment market through PDT-based drug-device combinations and ongoing research and development efforts.
Average Trading Volume: 478,383
Technical Sentiment Signal: Strong Sell
Current Market Cap: $9.9M
For detailed information about BFRI stock, go to TipRanks’ Stock Analysis page.